Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Shares Outstanding (Weighted Average) (2016 - 2025)

Marimed (MRMD) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $392.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.74% to $392.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $392.6 million, a 3.74% increase, with the full-year FY2024 number at $379.2 million, up 4.33% from a year prior.
  • Shares Outstanding (Weighted Average) was $392.6 million for Q3 2025 at Marimed, up from $386.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $392.6 million in Q3 2025 to a low of $305.2 million in Q1 2021.
  • A 5-year average of $353.8 million and a median of $352.1 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 32.22% in 2021, then rose 1.96% in 2025.
  • Marimed's Shares Outstanding (Weighted Average) stood at $326.5 million in 2021, then grew by 3.44% to $337.7 million in 2022, then increased by 7.61% to $363.4 million in 2023, then rose by 4.33% to $379.2 million in 2024, then grew by 3.55% to $392.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Shares Outstanding (Weighted Average) are $392.6 million (Q3 2025), $386.2 million (Q2 2025), and $382.6 million (Q1 2025).